Compare Hut 8 Corp (HUT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Merck & Co., Inc. — how do they compare? Hut 8 Corp trades at $91.77 (market cap $10.94B), while Merck & Co., Inc. trades at $133.5 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 29.4× Hut 8 Corp's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| HUT | MRK | |
|---|---|---|
Market Cap | $10.94B | $321.77B |
Sector | Technology | Health |
52-Week High | $133.02 | $131.84 |
52-Week Low | $21.37 | $77.60 |
Enterprise Value | $18.38B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $91.66, up 7.0% today amid a broader neocloud rally following NVIDIA's $500 billion AI pledge. The stock shows a bearish technical trend with support at $87 and resistance at $92. Fundamentally, Q2 2026 revenue grew 81% year-over-year to $74 million, but net losses widened to -$226 million in 2025. The company is transitioning to an AI data center platform, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (94%) targets $165.11, citing AI infrastructure potential, but high execution risks and persistent losses pose threats. Near-term volatility is likely as the market weighs Beacon Point commercialization progress against earnings misses and negative cash flow from operations.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
